Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fully human anti-VEGF antibodies and methods of using

A technology of antibodies and antigens, which is applied in the field of treatment of medical diseases such as cancer, and can solve problems that are difficult to achieve

Inactive Publication Date: 2010-12-15
SCHERING AG +1
View PDF32 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Such an antibody poses a great technical challenge and is very difficult to achieve, as merely increasing the binding affinity of a VEGF antibody does not necessarily increase its potency in vivo (Liang 2006)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fully human anti-VEGF antibodies and methods of using
  • Fully human anti-VEGF antibodies and methods of using
  • Fully human anti-VEGF antibodies and methods of using

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0460] Example 1: Binding hVEGF 165 The production of antibodies:

[0461] For fixed hVEGF 165 Panning of human single-chain Fv (scFv) phage display library to identify binding hVEGF 165 A set of antibody fragments of ability. Use standard protocols for panning (see, for example, Methods in Molecular Biology, vol.178: Antibody Phage Display: Methods and Protocols Edited by PMO'Brien and R. Aitken, Humana Press; "Panning of AntibodyPhage-Display Libraries," Coomber. DWJ, PP. 133-145, and "Selection of Antibodies Against Biotinylated Antigens," Chames, P. et al., pp. 147-157).

[0462] Briefly, use 50μl of recombinant hVEGF at a concentration of 10μg / ml in PBS 165 (R&D Systems, catalog number: 293-VE) Coating Three holes of the MAXISORP board. After overnight incubation at 4°C, free binding sites were blocked with 5% milk PBS solution for 1 hour at room temperature. Then, about 200 μl of the phage library in 5% milk / PBS was added to the closed wells and incubated at room tempe...

Embodiment 2

[0464] Example 2: Targeting hVEGF by scFv 165 Blocking of VEGF receptor binding:

[0465] Use microplate-based competitive screening Assay (Perkins Elmer, Waltham, MA), the ELISA in Example 1 showed that it is 165 Bound phage clones test them to block hVEGF 165 The ability to bind to VEGF-R1 and / or VEGF-R2.

[0466] Briefly, the biotinylated hVEGF 165 The solution was added to the cytoplasmic extract of Example 1 in a volume ratio of 1:1 to reach a final concentration of 0.5 μg / ml. Add 100 μl of this mixture to VEGF-R1 or VEGF-R2 (R&D Systems: VEGF-R1 / Flt-1, catalog number: 321-FL; VEGF-R2 / KDR / Flk-1, catalog number: 357-KD) Coated plates and incubate at room temperature for 1.5 hours. The plate was washed with PBST, and a 1:250 dilution of europium-streptavidin in DELFIA assay buffer was added in an amount of 50 μl / well. The plate was incubated for 1 hour at room temperature and then washed with DELFIA washing buffer. DELFIA enhancement buffer was added in an amount of 50 μ...

Embodiment 3

[0467] Example 3: Conversion of scFv to scFv-Fc and IgG

[0468] HVEGF 165 Two scFvs (XPA.10.064 and XPA.10.072) that inhibited binding to VEGF-R1 or VEGF-R2 by more than 60% were used for the conversion to scFv-Fc and / or IgG. figure 1 The heavy chain variable regions (including heavy chain CDRs) and light chain variable regions (including light chain CDRs) of XPA.10.064 and XPA.10.072 are shown. The heavy chain CDRs (e.g., HCDR1, HCDR2 and HCDR3) and light chain CDRs (for example, HCDR1, HCDR2 and HCDR3) are determined by the Kabat numbering system (Kabat, EA, et al. 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA) For example, LCDR1, LCDR2 and LCDR3). The HCDR1, HCDR2, and HCDR3 amino acid sequences of XPA.10.064 and XPA.10.072 are shown in SEQ ID NOs: 6, 7, and 8, respectively. The LCDR1, LCDR2, and LCDR3 amino acid sequences of XPA.10.064 are shown in SEQ ID NOs: 12, 13, and 14, respectively. The LCDR1, LCDR2, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.

Description

[0001] Related application [0002] This patent application claims the priority of U.S. Provisional Application No. 60 / 981,808 filed on October 22, 2007 and U.S. Provisional Application No. 61 / 046,370 filed on April 18, 2008. The entire contents disclosed in these applications, including the drawings, are incorporated herein by reference. Background technique [0003] Vascular endothelial growth factor (VEGF) is a major family of angiogenic proteins involved in endothelial cell activation, proliferation and survival, especially during retinal proliferative diseases and tumorigenesis. VEGF belongs to the VEGF-PDGF (platelet-derived growth factor) supergene family and is a small glycoprotein dimer that binds to receptors expressed in blood vessel and lymphatic endothelial cells. Currently, there are seven known ligands in the VEGF family: VEGF-A (VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E (viral origin) and placental growth factor (PIGF)-1 And -2. These VEGF ligands mediate their effec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12P21/08
CPCY10S435/81C07K2317/622C07K2319/00C07K2317/52C07K2317/92C07K2317/21C07K16/22A61K2039/505C07K2317/73C07K2316/96C07K2317/76A61P11/06A61P17/00A61P19/02A61P27/02A61P29/00A61P35/00A61P5/00A61P9/00A61P3/10
Inventor 舒曼特·拉马钱德拉沃尔特·罗伯特·毕晓普琳达·马萨特黄超白竹内俊彦西玛·坎塔克黄清仪
Owner SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com